Persistence of glaucoma medical therapy in the Glasgow Glaucoma Database

Rahman, Mustafizur; Abeysinghe, S S; Kelly, Steven; Roskell, Neil; Shannon, P R; Abdlseaed, Abdlsaed Al; Montgomery, Donald

doi:10.1136/bjo.2010.188607

Cited by 12 publications

(7 citation statements)

References 21 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have previously described, in this journal, a large and unique computerised database established at the glaucoma clinic at Glasgow Royal Infirmary, with data now spanning 27 years 8 9. We now present our findings on the total direct healthcare-related costs for glaucoma management in a population of patients for whom we have complete lifetime data.…”

Section: Introductionmentioning

confidence: 99%

Direct healthcare costs of glaucoma treatment

Rahman

Beard²,

Discombe

et al. 2013

Br J Ophthalmol

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Direct healthcare costs of glaucoma treatment

Rahman

Beard²,

Discombe

et al. 2013

Br J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…The results of the great majority of these studies (summarized in Table 3 ) show that treatment compliance and persistence are better with latanoprost eye drops than with other medications. 105 , 108 – 110 , 112 , 113 , 115 – 118 However, this finding is not unequivocal, with two studies finding either an equivocal advantage or no advantage for latanoprost in comparison with other glaucoma treatments. 114 , 120…”

Section: Prostaglandinsmentioning

confidence: 99%

Latanoprost in the treatment of glaucoma

Alm

2014

OPTH

View full text Add to dashboard Cite

Prostaglandins are approved by the European Glaucoma Society guidelines as first-line treatment for glaucoma. This review focuses on latanoprost, an ester prodrug of prostaglandin (PG) F2α, which was the first of the currently available topical PGF2α analogs to be launched for glaucoma or ocular hypertension and which still accounts for the majority of prescriptions. It is better absorbed than the parent compound through the cornea, and peak concentration of the active drug is in the aqueous humor 1–2 hours after topical dosing (15–30 ng/mL). Metabolism occurs mainly in the liver. Latanoprost (0.005%) has been very well studied in clinical trials and meta-analyses that show it to be generally as effective as the other PG analogs (bimatoprost, travoprost, and tafluprost) and more effective than timolol, dorzolamide, and brimonidine. Latanoprost has good short- and long-term safety and tolerability profiles. In common with other prostaglandins, it lacks systemic effects, but can cause ocular adverse events such as conjunctival hyperemia, pigmentation of the iris, periocular skin or eyelashes, hypertrichosis, and ocular surface effects or irritation. Latanoprost is significantly better tolerated than either bimatoprost or travoprost. Patients treated with latanoprost have better compliance and persist with therapy longer than those that are given other drugs. An improved formulation of latanoprost without the preservative benzalkonium chloride has recently been developed. It is as effective as conventional latanoprost, has a lower incidence of hyperemia, and can be stored at room temperature. In conclusion, latanoprost has the best efficacy–tolerability ratio of the PG analogs available for glaucoma treatment, and has good compliance and persistence. These factors should be improved further by the recent development of preservative-free latanoprost.

show abstract

“…Brimonidine has an unfavorable side-effect profile that leads to reduced persistency rates compared with other commercially available glaucoma medicines [19]. Therefore, it is not surprising that the dropout rate in the brimonidine arm of the LoPGTS study was higher than the dropout rate in the timolol arm.…”

Section: Editorialmentioning

confidence: 99%